Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
… in modern medicine. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), currently licensed for the treatment of type 2 diabetes melli…
…erans Affairs healthcare system with type 2 diabetes initiating GLP-1RA (n=132 551) or sulfonylureas (n=201 136) between 1 January 2017…
…ratified by weight cycling status.Interventions Weight loss via GLP-1RAs with or without HP-ONS for weight maintenance.Primary and secon…
…aluate the effect of Glucagon-like peptide-1 receptor agonists (GLP-1RAs) use on the incidence of ICH and mortality in patients with unr…
…analyses were directionally consistent.Conclusion Postoperative GLP-1RA initiation, compared with DPP-4i initiation, was associated wit…
… outcome (10%), and incident CKD stages 3–4 (23%) compared with glipizide. However, glyburide was associated with significantly higher ri…
…ufactured GLP-1RA products (active ingredients: liraglutide and semaglutide) in people with type 2 diabetes and/or overweight/obesity. Pote…
…cial in these patients. Remarkably, the benefits of GLP-1RA and SGLT2i are independent of type 2 diabetes status or baseline renal fun…
…he results of the ongoing SEPRA trial, we found that injectable semaglutide was superior to SoC with 30% more patients achieving A1C <7% at…
… CI 47.2% to 54.7%) (8.2 million) met indications for either an SGLT2i or a GLP-1RA. Among those with indications for an SGLT2i specif…